Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a phase I - II multicenter, non-comparative, open label study in patients with
previously treated CLL aimed at defining the MTD of Lenalidomide given in combination with
Fludarabine, Cyclophosphamide and at evaluating the (CR) rate of FC given in combination with
the MTD of Lenalidomide (FCL).